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Enhancing excitatory activity of 
somatosensory cortex alleviates 
neuropathic pain through 
regulating homeostatic plasticity
Wenhui Xiong1,4, Xingjie Ping1,4, Matthew S. Ripsch2, Grace Santa Cruz Chavez5, Heidi Elise 
Hannon3,4, Kewen Jiang1,6, Chunhui Bao7, Vaishnavi Jadhav2, Lifang Chen1,8, Zhi Chai9, 
Cungen Ma9, Huangan Wu  7, Jianqiao Feng8, Armin Blesch  3,4, Fletcher A. White1,2,10 & 
Xiaoming Jin1,3,4
Central sensitization and network hyperexcitability of the nociceptive system is a basic mechanism 
of neuropathic pain. We hypothesize that development of cortical hyperexcitability underlying 
neuropathic pain may involve homeostatic plasticity in response to lesion-induced somatosensory 
deprivation and activity loss, and can be controlled by enhancing cortical activity. In a mouse model 
of neuropathic pain, in vivo two-photon imaging and patch clamp recording showed initial loss and 
subsequent recovery and enhancement of spontaneous firings of somatosensory cortical pyramidal 
neurons. Unilateral optogenetic stimulation of cortical pyramidal neurons both prevented and reduced 
pain-like behavior as detected by bilateral mechanical hypersensitivity of hindlimbs, but corpus 
callosotomy eliminated the analgesic effect that was ipsilateral, but not contralateral, to optogenetic 
stimulation, suggesting involvement of inter-hemispheric excitatory drive in this effect. Enhancing 
activity by focally blocking cortical GABAergic inhibition had a similar relieving effect on the pain-like 
behavior. Patch clamp recordings from layer V pyramidal neurons showed that optogenetic stimulation 
normalized cortical hyperexcitability through changing neuronal membrane properties and reducing 
frequency of excitatory postsynaptic events. We conclude that development of neuropathic pain 
involves abnormal homeostatic activity regulation of somatosensory cortex, and that enhancing 
cortical excitatory activity may be a novel strategy for preventing and controlling neuropathic pain.
Neuropathic pain is a major public health problem that affects 7–10% of the general population1. It is often 
caused by a primary lesion of the nervous system such as nerve or spinal cord injury, which leads to maladaptive 
plasticity and central sensitization of the nociceptive pathways2. The resulting neuronal hyperexcitability and 
ectopic spontaneous firing are believed to be key pathophysiological mechanisms2,3. Accordingly, suppressing 
such hyperexcitability and aberrant activity by directly inhibiting network excitability or enhancing inhibition is 
a generally accepted paradigm for the management of neuropathic pain4. However, the current pharmacological 
treatments only produce partial pain relief in a portion of the patients5.
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Injury-induced loss of cortical activity is known to trigger homeostatic regulation of activity, a well-established 
mechanism in which cortical neurons dynamically regulate their synaptic strengths and intrinsic properties 
in response to an imposed increase or decrease of synaptic input so that a relatively constant activity level is 
maintained6–10
Thus, hyperexcitability, which underlies neuropathic pain, may be initiated and maintained via a homeostatic 
mechanism that more than compensates for loss of input from injured pathways. After some types of spinal 
cord injury, primary somatosensory cortex (S1) exhibits initial activity loss and subsequent hyperexcitability and 
paroxysmal discharges11–13, consistent with homeostatic activity regulation. Because the injury-induced changes 
are often permanent or progressive, such homeostatic compensation likely results from constant or progressive 
loss of activity in the associated cortex. In turn, restoration of this activity by cortical stimulation would reduce 
pathological homeostatic regulation and control neuropathic pain. Indeed, cortical stimulation techniques such 
as motor cortical stimulation and repetitive transcranial magnetic stimulation have been used for patients with 
refractory neuropathic pain14,15. Although studies suggest that activation of brain inhibitory pathways or descend-
ing projections may contribute to the analgesic effect, the mechanisms are poorly understood16,17. Particularly, the 
direct effect of cortical stimulation on the neurophysiology of cortical neurons themselves has not been directly 
investigated.
Using a transient spinal cord ischemia model (tSCI) of neuropathic pain in mice18,19, we studied the mani-
festation of homeostatic plasticity in the S1 in vitro and in vivo, and demonstrated that optogenetic or pharma-
cological enhancement of cortical activity diminished injury-induced behavioral hypersensitivity in this model. 
Mechanistically, we used patch clamp recording to demonstrate changes in neuronal intrinsic properties and syn-
aptic transmission after injury, and the effect of optogenetic stimulation in reversing most of the injury-induced 
electrophysiological alterations. Our results suggest that the development of neuropathic pain involves homeo-
static regulation and that enhancing cortical excitatory activity can control neuropathic pain.
Results
Homeostatic regulation of spontaneous activity after tSCI in vivo and in vitro. We first identi-
fied the location of the hindlimb area of the S1 (HL-S1) based on the maximum amplitude of sensory-evoked 
potential (SEP) induced by electrically stimulating the hind paw of naïve mice in vivo (n = 4 mice). A rectangular 
HL-S1 area was found to span 1.5–2 mm laterally and 2 mm in an anterolateral and posteromedial direction, 
with the medial border being ~1 mm lateral to the midline and the longitudinal center being ~1 mm posterior to 
the bregma (Fig. 1A). All subsequent in vitro and in vivo experiments in this study were targeted to this cortical 
region.
To determine whether and how a lesion to the somatosensory pathway affects neuronal activity of S1 in vivo, 
we used a repeated two-photon imaging technique to measure activity changes of cortical layer II/III pyramidal 
neurons in GCaMP6s transgenic mice that were sedated with chlorprothixene20,21. The HL-S1 area of each mouse 
was repeatedly imaged at baseline and 6, 18, 24, and 48 hours after sham injury or tSCI (Fig. 1B-C, 356 cells from 
7 sham-injured mice and 327 cells from 7 tSCI mice). Under baseline or sham-injured conditions, activities of 
fluorescent cells were clearly visible. At 6 hours post-tSCI, both the mean integrated fluorescence (for measur-
ing intensity of spiking activity of individual neurons) and fraction of active neurons (those that fired at least 
once during the imaging period) were dramatically reduced when compared with the sham group or baseline 
level of the tSCI group (Fig. 1B–E, repeated-measurement ANOVA followed by Bonferroni tests, p < 0.05-0.001, 
n = 7 mice in each group), suggesting an initial loss of activity. They recovered to about baseline levels in 18 and 
24 hours after injury, but the ratio of active neurons in the tSCI group became significantly higher than its base-
line level and that of the sham group at 48 hours (both p < 0.05). In contrast, there were no significant changes at 
different time points in integrated fluorescence and ratio of active cells in the sham group.
We further recorded spontaneous action potential (AP) firing of layer V pyramidal neurons in brain slices 
from the HL-S1 in a modified artificial cerebrospinal fluid (ACSF) that slightly increases neuronal activity22,23. 
The spike frequency at 6 hours after tSCI became significantly lower (Fig. 2A,B, 1.72 ± 0.44 and 0.26 ± 0.10 Hz for 
sham and 6-hour groups respectively, p < 0.05, Mann-Whitney test, n = 4–8 mice in each group), and recovered 
at 1 day and 3 days post-tSCI (p < 0.001 and p < 0.01 respectively, Mann-Whitney test). At 7 days and 14 days 
post-tSCI, the frequencies were significantly higher than the sham and 6 hours post-tSCI groups (3.22 ± 0.63 and 
5.13 ± 0.77 Hz, p < 0.05 and p < 0.001 respectively, Mann-Whitney test). Thus, the observed in vivo and in vitro 
transitions from initial activity loss to enhanced spontaneous activity suggest a homeostatic regulation of cortical 
activity following tSCI.
Optogenetic stimulation of the S1 prevented pain-like behavior in two models of neuropathic 
pain. To specifically activate cortical excitatory neurons, we used a miniature blue light-emitting diode (LED, 
~470 nm peak wavelength) to optogenetically stimulate S1 activity in ChR2 transgenic mice in which the cortical 
expression of ChR2 is mostly in layer V pyramidal neurons (Fig. 3A).
The LED was driven by a wired miniature circuit we made to generate a burst of 3 pulses at 33 Hz every 3 sec-
onds. To confirm the effectiveness of LED stimulation, we recorded EEG and found that the light pulses induced a 
precise bursting response of the cortex (Fig. 3A, n = 3 mice). To further confirm the effect of the light stimulation 
on activating neurons, we made c-fos staining of cortical slices under different conditions. In naïve, unstimulated 
mice, few cells were stained by c-fos antibody (Fig. 3B). Following a 1.5 hour bursting stimulation using the LED 
in either normal uninjured mice or tSCI mice, an increased number of c-fos expressing neurons were visible in 
cortical layer II/III and layer V of the S1 region, but much less in regions outside of the targeted S1 (Fig. 3B, n = 4 
mice in each group), suggesting focal activation of cortical neurons by the optogenetic stimulation.
Because a recent study showed that light stimulation of the brain can induce rapid and transient vasodila-
tion without activating neurons and astrocytes24, we tested whether our optogenetic stimulation could change 
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cerebral blood circulation. Cerebral blood vessels were visualized by intravenous injection of a fluorescence dye 
Sulforhodomine 101 and imaged through a cranial window (Fig. 3C,D). Following 15 minutes of LED stimula-
tion, in vivo two-photon imaging of fluorescence labeled cerebral vessels showed no significant changes in the 
Figure 1. Repeated in vivo two-photon imaging revealed S1 activity changes of adult mice after tSCI. (A) The 
location of hindlimb S1 area (HL-S1, yellow regions) was identified by applying electrical stimulation (0.2 mA 
and 200 μs) to the hind paw and recording cortical sensory evoked potentials in vivo (n = 4 mice). Each dot 
on the right cortical surface corresponds to a recording trace on the right. The distances between neighboring 
traces were 1 mm. A rectangular HL-S1 area was found to span 1.5–2 mm laterally and 2.5–3 mm in an 
anterolateral and posteromedial direction, with the medial border being ~1 mm lateral to the midline and the 
longitudinal center being ~1 mm posterior to the bregma. The mouse brain image was created with Allen Mouse 
Brain Atlas using Brain Explorer® 2 (©2014 Allen Institute for Brain Science. Allen Mouse Brain Atlas: http://
mouse.brain-map.org/). (B) Average projections of the same regions of cortical layer II/III GCaMP6-expressing 
neurons at different time points after sham (top) and tSCI (bottom) surgery. (C) ΔF/F traces of calcium 
transients of neurons of sham and tSCI groups that correspond to the color-circled neurons in (A). (D) Changes 
in mean integrated fluorescence of the tSCI and sham groups indicate a loss of neuronal activity at 6 hours post-
tSCI followed by recovery, suggesting homeostatic regulation of activity after tSCI in vivo (n = 7 mice in each 
group). (E) There is a similar pattern of change when the ratios of active neurons are quantified and compared. 
However, the ratio of active neurons in tSCI group at 48 hours was significantly higher than that of the sham 
group and the baseline of the tSCI group. For graphs (D and E), repeated measure ANOVA was followed by 
Bonferroni test. *p < 0.05 and ***p < 0.001 when compared with the baseline of the tSCI group; #p < 0.05 and 
###p < 0.001 when compared between sham and tSCI groups at corresponding time points.
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velocity of red blood cells (RBC) and vessel diameters of arterioles and venules between before and after light 
stimulation (Fig. 3E,F, n = 4 mice in each group). The results suggest that our light stimulation protocol did not 
induce detectable changes in cerebral blood circulation.
The homeostatic plasticity hypothesis predicts that stimulating cortical activity would reduce neuronal hyper-
excitability and prevent neuropathic pain. To test this hypothesis, we used the blue LED to optogenetically stim-
ulate S1 of Thy1-ChR2 transgenic mice on the second day after tSCI25. Applying the optogenetic stimulation to 
unilateral S1 for two sessions of 3 hours daily results in a highly significant decrease in mechanical hypersensitiv-
ity of bilateral hind-paws, and this effect was significant as early as 3 days after tSCI and remained stable through-
out the stimulation period (Fig. 4A, p < 0.001 for both sides, repeated-meaure ANOVA followed by Bonferroni 
tests, n = 6 mice in each group). However, the effect on the ipsilateral hindlimb had a later onset and was smaller 
in magnitude than the contralateral hindlimb (Fig. 4A).
Optogenetic stimulation of the S1 in ChR2 mice may activate ChR2 axons that pass through the S1 region and 
activate remote cortical synapses or neuronal somata. To provide more precise stimulation of the S1, we injected 
a CaMKIIa.hChR2(H134R)-mCherry AAV virus into the S1 and repeated the experiment 2 weeks later. The 
virus transfected S1 pyramidal neurons within an area of ~1–1.5 mm diameter (Fig. 4B). Optogenetic stimulation 
with the same protocol induced a significant increase in the threshold of Von Frey test of the contralateral hind 
paw at day 5 and 7 after tSCI (Fig. 4C, p < 0.05 and p < 0.01 respectively, repeated-measure ANOVA followed 
by Bonferroni tests, n = 5 mice in each group). The results support the efficacy of S1 optogenetic stimulation in 
relieving pain-like behavior in the tSCI model.
To determine the effects of tSCI and optogenetic stimulation on S1 excitability in vivo, we recorded cortical 
sensory evoked potentials (SEPs) before and after tSCI. We found that tSCI caused a significant increase in the 
amplitude and a significant decrease in the latency of SEPs at 5 days after injury (Fig. 4D–F, p < 0.05, paired t-test, 
n = 8 mice). In contrast, optogenetic stimulation for 5 days resulted in unchanged amplitude and latency of the 
SEPs (Fig. 4D–F, n = 5 mice). The results suggest that optogenetic stimulation of S1 reduces the hyperexcitability 
of the somatosensory pathway.
We further tested the effect of S1 optogenetic stimulation in a tibial nerve injury (TNI) model of neuropathic 
pain. Application of the same optogenetic stimulation on S1 for 1 week greatly reduced mechanical hypersensitiv-
ity of the contralateral hind-paw, as measured with the Von Frey test (Fig. 5. p < 0.001, repeated measure ANOVA 
followed by Bonferroni test, n = 6 mice in each group). Furthermore, the analgesic effect lasted for > 2 weeks after 
turning off the LED (Fig. 5. p < 0.001 to p < 0.05), indicating a lasting effect of the stimulation on controlling 
hypersensitivity development.
Optogenetic stimulation of the S1 reduced pain-like behavior via excitatory drive. To further 
determine whether the bilateral analgesic effect of unilateral optogenetic stimulation was mediated by an excita-
tory drive carried by optogenetically stimulated layer V pyramidal neuron axons to the homotopic contralateral 
cortex through the corpus callosum, we tested the effect of transecting the corpus callosum between S1 regions 
of the two cortical hemispheres of tSCI + LED mice on day 28 post-tSCI. The transection of corpus callosum was 
confirmed by DiI stained axotomized axons in white matter in 3 mice. The result showed that the corpus calloso-
tomy spanned ~4 mm rostroventrally and truncated interhemispheric axons between S1 of the two hemispheres 
Figure 2. Development of elevated spontaneous activity in S1 of the tSCI mice. (A).Representative traces of 
spontaneous AP firing in layer V pyramidal neurons in cortical slices from the HL-S1 of the sham group and 
at different times post-tSCI. Recordings were made at −60 mV in a modified ACSF that slightly enhanced 
spontaneous firing (n = 4–8 mice in each group). (B) Spike frequencies in different groups (1.72 ± 0.44 Hz, 
0.26 ± 0.10 Hz, 1.23 ± 0.77 Hz, 1.72 ± 0.52 Hz, 3.22 ± 0.63 Hz, and 5.13 ± 0.77 Hz for the sham, 6 hour, 1 day, 
3 day, 7 day and 14 day groups respectively). There was a significant decrease in spike frequency at 6 hours post-
tSCI (p < 0.05 when compared with the sham group), which was followed by a progressive increase in spike 
frequency between 3–14 days post-tSCI. Spike frequency in the 3 day group was higher than 6 hour and 1 day 
groups, and spike frequencies in 7 day and 14 day groups were higher than the sham, 6 hour, and 1 day groups. 
*p < 0.05; **p < 0.01; *** < 0.001; Mann-Whitney test). The numbers on top are numbers of recorded neurons 
in each group.
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(Fig. 6A, n = 3 mice). C-fos staining showed that optogenetic stimulation of unilateral S1 activated neurons of the 
ipsilateral cortex (Fig. 6B, left), but not the contralateral S1 (Fig. 6B, right), further confirming that the callosot-
omy eliminated the effect of optogenetic stimulation on activating neurons of the contralateral cortex.
Figure 3. Activation of S1 neurons using optogenetic stimulation in ChR2 mice. (A) Chronic optogenetic 
stimulation was made by implanting a blue LED (475 nm) on a cranial window over the S1 area of the Thy1-
ChR2-YFP transgenic mice (left). About 1.5 mm diameter area of the window was exposed to the LED, with the 
surrounding area being blocked by opaque tape. Cortical expression of ChR2 is mostly in layer V pyramidal 
neurons (insert). The effectiveness of LED stimulation was confirmed by the evoked spikes of EEG recording 
(right) in vivo. (B) C-fos staining of cortical slices indicates activation of cortical neurons by the optogenetic 
stimulation. There was little staining in the cortex of naïve mice without optogenetic stimulation (top panel). 
For each row, c-fos staining of the ipsilateral (left two columns) and contralateral (right two columns) cortex are 
shown; enlarged views of the white square areas are shown to the right. The dotted lines indicate approximate 
borders of activated cortical neurons. After turning on blue light pulses (see methods) for 1.5 hours, there were 
c-fos positive cells in layer II/III and V in the S1 regions of both ipsilateral and contralateral hemispheres in 
uninjured ChR2 mice (middle panel). Similar bilateral c-fos staining pattern was seen in tSCI mice that received 
1.5 hours LED stimulation (bottom panel). C–F No significant changes in cerebral vessel diameter and blood 
flow after light stimulation. Cerebral vessels were visualized by intravenous injection of sulforhodamine 101 
in wild C57BL mice and imaged with two-photon microscopy (C). Cortical superficial arterioles and venules 
were identified and imaged in line scan mode (D). After 15 minutes of blue LED light stimulation, there were no 
significant changes in the velocities of red blood cells (RBC) and vessel diameters of arterioles and venules (E 
and F, n = 4 mice). Scale bars: A = 400 µm; B (1st and 3rd columns) = 500 µm; B (2nd and 4th columns) = 50 µm; 
C = 80 µm.
www.nature.com/scientificreports/
6SCieNTifiC REPORts | 7: 12743  | DOI:10.1038/s41598-017-12972-6
Figure 4. Optogenetic stimulation of S1 prevents the development of mechanical hypersensitivity and reduces 
cortical hyperexcitability. (A) Optogenetic stimulation of the S1 in the tSCI model resulted in significant 
increases in withdrawal threshold forces of the bilateral hind-paws (***p < 0.001 when stimulated and 
unstimulated mice were compared; repeated measure ANOVA followed by Bonferroni test, n = 6 mice in each 
group). (B,C) Focal S1 optogenetic stimulation in virus transfected mice also induced analgesic effect. Following 
injection of ChR2-mCherry AAV into the S1 to infect layers II/III and V pyramidal neurons in a focal region 
(B), optogenetic stimulation with the same protocol also induced significant analgesic effect in the tSCI model 
(C). (*p < 0.05; **p < 0.01 when the tSCI + LED group was compared with the tSCI control group; Repeated 
measure ANOVA, n = 5 mice in each group). Scar bar: 300 µm. (D) Sample traces show that tSCI caused a high 
amplitude of cortical sensory-evoked potential, but optogenetic stimulation with LED for 5 days normalized it. 
(E,F) Group data showed that there were higher amplitudes of sensory-evoked response in tSCI group but not 
tSCI + LED group (E) and shorter latency in tSCI group but not tSCI + LED group (F). *p < 0.05, paired t-test 
in both E and F (tSCI group: n = 8 mice; tSCI + LED group: n = 5 mice).
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To determine whether S1 optogenetic stimulation would be effective in reducing neuropathic pain that has 
already developed, we applied delayed optogenetic stimulation at day 14 post-tSCI. While optogenetic stim-
ulation had no effect on the pain threshold in mice of the sham group, it caused significant increases in the 
withdrawal threshold of bilateral hind-paws in the tSCI group at days 21 and 28 post-injury (Fig. 6C. p < 0.05, 
repeated measure ANOVA followed by Bonferroni test, n = 4-5 mice), suggesting that S1 optogenetic stimulation 
has a treatment effect on neuropathic pain. Following the corpus callosotomy, the analgesic effect of the hind-paw 
that was contralateral to optogenetic stimulation remained unchanged, but the effect of the hind-paw that was 
ipsilateral to optogenetic stimulation disappeared (Fig. 6C. p < 0.01 and p < 0.001). This result indicates that 
enhancing excitatory activity per se is likely responsible for the observed trans-hemispheric analgesic effect.
Optogenetic stimulation reduced neuronal intrinsic excitability and normalized synaptic trans-
mission of layer V pyramidal neurons. To determine the mechanism of S1 optogenetic stimulation on 
cortical hyperexcitability, we recorded from layer V pyramidal neurons in tSCI mice after 5 days of cortical opto-
genetic stimulation. The spontaneous firing rate in tSCI group was significantly higher than the sham group, but it 
decreased significantly after optogenetic stimulation (Fig. 7A. 2.0 ± 0.6, 4.1 ± 0.6, and 2.5 ± 0.6 Hz for sham, tSCI, 
and tSCI + LED groups respectively, both p < 0.05, One-way ANOVA followed by Bonferroni test), suggesting 
reduced excitability of these neurons after optogenetic stimulation.
We analyzed neuronal membrane properties under current clamp mode (Fig. 7B). There was no significant 
difference in resting membrane potentials among all groups (−63.6 ± 0.4, −63.1 ± 0.3, −63.9 ± 0.4 mV for 
the sham, tSCI, and tSCI + LED groups respectively, p > 0.05, One-way ANOVA), but there was a significant 
increase in input resistance after tSCI, which was decreased after optogenetic stimulation (Fig. 7C. 86.6 ± 6.0, 
105.5 ± 4.6, and 94.3 ± 3.3 MΩ for sham, tSCI, and tSCI + LED groups respectively, both p < 0.05). Furthermore, 
the tSCI + LED group had a more positive AP threshold than the tSCI group (Fig. 7D. −49.8 ± 1.1, −50.9 ± 0.6, 
and −48.2 ± 0.8 mV for sham, tSCI, and tSCI + LED groups respectively, p < 0.05, One-way ANOVA followed by 
Bonferroni test). These results indicate that these changes in intrinsic properties induced by optogenetic stimula-
tion contribute to reversing hyperexcitability of cortical pyramidal neurons after tSCI.
Homeostatic plasticity often involves changes in excitatory and inhibitory synaptic transmission10,26–28. We 
recorded miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs) from layer V pyram-
idal neurons of the S1. The mEPSC frequency of the tSCI group was significantly higher than that of the sham 
group, but it was reversed after optogenetic stimulation (Fig. 8A,B. 1.8 ± 0.4, 3.4 ± 0.5, and 1.3 ± 0.4 Hz for sham, 
tSCI, and tSCI + LED groups respectively, p < 0.05 when sham and tSCI or tSCI and tSCI + LED were compared). 
Interestingly, the amplitudes of mEPSCs were similar in the sham and tSCI groups, but it became larger after 
optogenetic stimulation (Fig. 8C. −9.8 ± 0.2, −9.4 ± 0.2, and −11.6 ± 0.6 pA for sham, tSCI, and tSCI + LED 
groups respectively, p < 0.001, one-way ANOVA followed by Bonferroni test). The cumulative probability 
curve of inter-event intervals had a left shift for the tSCI group relative to the sham group (Fig. 8D. p < 0.001, 
Kolmogorov–Smirnov [K-S] test), but a right shift for the tSCI + LED group (p < 0.005). There were no changes 
in mEPSC amplitude curves among all 3 groups (Fig. 8E, p > 0.05). Analyses of the rise time and decay time con-
stant of mEPSC in the 3 groups showed no significant differences among them (data not shown).
We recorded mIPSCs at a calculated mEPSC reversal potential of +10 mV (Fig. 9A). There were no signifi-
cant differences in mIPSC frequencies (Fig. 9B. p > 0.05, one-way ANOVA), but mIPSC amplitude of the tSCI 
groups was significantly higher than that of the sham group, which became normal after optogenetic stimulation 
(Fig. 9C. both p < 0.01, one-way ANOVA followed by Bonferroni test). There were no differences in cumulative 
probability curves of both mIPSC inter-event interval and amplitude among all groups (Fig. 9D,E. p > 0.05).
Pharmacological enhancement of excitatory activity also reduced neuropathic pain. The 
homeostatic plasticity hypothesis suggests that chronic pharmacological enhancement of cortical activity may 
also reduce neuropathic pain. To test this hypothesis, we used a GABAA receptor antagonist bicuculline to 
enhance cortical activity. Because neuronal injury can cause a positive shift of GABAA reversal potential and 
excitatory GABAergic response, we first used in vivo two-photon imaging in GCaMP6 mice to directly determine 
Figure 5. Analgesic effect of optogenetic stimulation in a TNI model: Light stimulation of the S1 for 7 days in 
a mouse TNI model also resulted in increases in hind-paw withdrawal threshold forces than the sham-injured 
mice. Furthermore, despite the cessation of the stimulation at day 7, the stimulated mice continued to have 
a higher pain threshold up to day 21. (*p < 0.05; ***p < 0.001 when compared to the TNI group; Repeated 
measure ANOVA, n = 6 mice in each group).
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Figure 6. Analgesic effect of S1 optogenetic stimulation is mediated by cortical excitatory drive. (A). A 
corpus callosotomy was made using a “L-shaped” needle coated with a lipophilic fluorescent dye DiI, which 
labeled both local cut path (gray triangle) and truncated inter-hemispheric axons (arrows) of the intact 
cortical hemisphere (n = 3 mice). (B). In a ChR2 mouse that received callosotomy, c-fos staining shows that 
optogenetic stimulation for 1.5 hours activated only neurons ipsilateral to the LED (top images), but not 
neurons contralateral to it (bottom images) (n = 3 mice). The white squares indicate the location of the enlarged 
areas on the right. (C). Delayed optogenetic stimulation started on day 15 post-tSCI (dotted line) resulted in 
significant increases in withdrawal threshold forces of bilateral paws at days 21 and 28 (n = 4–5 mice in each 
group, p < 0.05). However, corpus callosotomy on day 28 (black arrow) resulted in a loss of analgesic effect of 
the ipsilateral hind-paw, but not the contralateral hind-paw, to optogenetic stimulation (p < 0.05-0.001 when 
compared between ipsilateral and contralateral paws, repeated- measure ANOVA). Scale bars in A and B (left 
column): 500 µm; B (right column): 50 µm.
www.nature.com/scientificreports/
9SCieNTifiC REPORts | 7: 12743  | DOI:10.1038/s41598-017-12972-6
whether bicuculline would increase cortical activity. Application of 20 mM bicuculline solution on the pial sur-
face caused a dramatic increase in cortical spontaneous activity, which soon turned into highly synchronized, 
rhythmic epileptiform activities (Fig. 10A, n = 2 mice). The result indicates that bicuculline enhances cortical 
activity in the tSCI model.
Figure 7. Optogenetic stimulation normalizes enhanced spontaneous firing and excitability of cortical layer V 
pyramidal neurons after tSCI. (A) Spike frequency of cortical layer V pyramidal neurons at 10 days after tSCI 
was significantly higher than that of the sham group, and was reduced after 5 days of optogenetic stimulation 
(sham: 2.0 ± 0.6 Hz; tSCI: 4.1 ± 0.6 Hz, tSCI + LED: 2.5 ± 0.6 Hz. *: p < 0.05, Mann-Whitney test). Numbers 
in the bars indicate neuron numbers in each group; same for the following figures. (B) Representative traces 
of AP firing of layer V pyramidal neurons in response to current injections. (C) Neuronal input resistance in 
tSCI group was higher than that of the sham group, but after optogenetic stimulation it was significantly lower 
than the tSCI group (sham: 86.6 ± 6.0 MΩ; tSCI: 105.5 ± 4.6 MΩ; tSCI + LED: 94.3 ± 3.3 MΩ. p < 0.05 when 
compared between sham and tSCI groups, and between the tSCI and tSCI + LED groups, One-way ANOVA 
followed by Bonferroni test). (D) Optogenetic stimulation resulted in a more positive active potential threshold 
than the tSCI group (−49.8 ± 1.1 mV, −50.9 ± 0.6 mV, −48.2 ± 0.8 mV in sham, tSCI, and tSCI + LED groups 
respectively. *p < 0.05 when compared between tSCI and tSCI + LED groups, One-way ANOVA followed by 
Bonferroni test).
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We implanted on the S1 pial surface a slice of drug-releasing polymer Elvax that contained bicuculline or 
vehicle (saline) on the second day following tSCI. In contrast to mice that received saline-containing Elvax 
implants in which the implants had no effect on the pain threshold, mice that received bicuculline-containing 
Elvax implants had significantly higher pain thresholds on bilateral hind-paws (Fig. 10B). The analgesic effect 
of the bicuculline-Elvax group peaked at day 7 post-tSCI, and then gradually decreased in 2 weeks, likely due to 
drug depletion over time. A second implant of bicuculline-Elvax at day 21 post-tSCI maintained the analgesic 
effect for >2 additional weeks (Fig. 10B, p < 0.01-p < 0.001, Repeated measure ANOVA followed by Bonferroni 
test, n = 4 in blank-Elvax and n = 6 in bicuculline-Elvax group). Similar to optogenetic stimulation, unilateral 
bicuculline-Elvax implant has a bilateral analgesic effect. The result suggests that enhancing cortical activity by 
blocking GABAA receptor is effective in reducing mechanical hypersensitivity.
Discussion
Our data demonstrated homeostatic regulation of neuronal activity in the S1 following tSCI in vivo and in vitro, 
and the contributions of increased intrinsic excitability and mEPSC frequency to hyperexcitability of layer V 
pyramidal neurons. We found that optogenetic or pharmacological enhancement of cortical excitatory activity 
is sufficient to reduce the mechanical hypersensitivity associated with neuropathic pain. We further showed that 
optogenetic stimulation is able to effectively normalize neuronal intrinsic properties and synaptic transmission 
in the tSCI model. To our knowledge, this is the first demonstration that homeostatic activity regulation in the S1 
plays a role in the mechanism of neuropathic pain and that optogenetic or pharmacological enhancement of S1 
activity is effective in diminishing behavioral changes commonly observed with neuropathic pain.
Figure 8. Cortical optogenetic stimulation normalizes the elevated mEPSC frequency but increases mEPSC 
amplitude of layer V pyramidal neurons in tSCI mice. (A) Representative mEPSC traces from cortical layer 
V pyramidal neurons of the sham, tSCI, and tSCI + LED groups. (B) mEPSC frequency in tSCI group was 
significantly higher than the sham group, but became normal after optogenetic stimulation for 5 days (sham: 
1.8 ± 0.4 Hz; tSCI: 3.4 ± 0.5 Hz; tSCI + LED: 1.3 ± 0.4 Hz. *p < 0.05, one-way ANOVA followed by Tukey 
test). (C) tSCI resulted in no significant change in the amplitude of mEPSC (p > 0.05), but optogenetic 
stimulation caused a significant increase in the amplitude of mEPSC (Sham: −9.8 ± 0.2 pA; tSCI: −9.4 ± 0.2 
pA; tSCI + LED: −11.6 ± 0.6 pA. ***p < 0.001 when tSCI + LED group was compared with the sham or tSCI 
groups). (D) Cumulative histograms of inter-event intervals. The leftward shift of the tSCI curve indicates 
reduced inter-event intervals, and the rightward shifts of the tSCI + LED indicates increased inter-event 
intervals after stimulation (***p < 0.001 and **p < 0.01 for tSCI and tSCI + LED groups when compared to 
the sham group respectively, K-S test). (E) There were no significant differences in cumulative distribution of 
mEPSC amplitude among the 3 groups (p > 0.05).
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We targeted the S1 because of its critical involvement in pain perception29. Increasing evidence suggests that 
S1 is involved in nociceptive perception in both rodents30,31 and human32. Specifically, S1 plays a prominent and 
highly modulated role in nociception, including coding location, intensity, and duration of pain sensation29,33. S1 
synaptic plasticity has been demonstrated in models of neuropathic pain and S1 activation is associated with pain 
perception12,31,34–37, while inhibiting S1 plasticity or activity has the effect of reducing or preventing the develop-
ment of pain36,37.
Retina lesion or monocular visual deprivation has been shown to cause homeostatic activity regulation in the 
adult visual cortex10,38. Transient spinal cord ischemia is known to cause motor neuron death, white matter lesion, 
and inflammatory responses of the affected spinal cord segments18,39–41. Impaired motor function lasts for a few 
days followed by recovery42. Together with the long-lasting pain-like behavior, these pathological changes suggest 
likely involvements of damage to the nociceptive pathways in this model. Our finding of initial activity loss after 
tSCI followed by a state of hyperexcitability in S1 supports homeostatic activity regulation. Similarly, traumatic 
spinal cord injury also results in slower and more silent cortical spontaneous activity in the deafferented cortex 
as well as in the neighboring cortex during an earlier time period11,13. Weeks later, neurons in layer IV and V of 
the S1 have higher spontaneous firing rates and an increased tendency to fire bursts of APs43, and electrical stim-
ulation induces a stronger and enlarged area activation of the S112. These sequential changes in neuronal activity 
support homeostatic regulation of activity in the S1 following tSCI.
It appears that changes in intrinsic properties and synaptic input both contribute to S1 hyperexcitability. The 
increased input resistance of the neurons will make their received synaptic input more efficient in changing mem-
brane potential. A ~90% increase in the frequency and unchanged amplitude of mEPSCs will greatly enhance 
excitatory drive to the pyramidal neurons likely through a presynaptic mechanism, while the increase (~5%) in 
mIPSC amplitude was small. Together, the net effect of these changes is a shift towards enhanced excitation of the 
cortical network in the cortex following tSCI.
Sensory deprivation also causes plasticity and reorganization of the S1, which may be related to the develop-
ment of neuropathic pain37,44,45; reversing it is effective in relieving neuropathic pain behavior46. However, such 
Figure 9. Cortical optogenetic stimulation normalizes the increased mIPSC amplitude of layer V pyramidal 
neurons in tSCI mice. (A) Representative mIPSC traces of the 3 groups at a holding potential of + 10 mV. (B) 
There were no significant differences in the mean frequency of mIPSCs among all groups (sham: 11.5 ± 0.7 Hz; 
tSCI: 13.0 ± 0.5 Hz; tSCI + LED: 11.8 ± 0.9 Hz. p > 0.05). (C). The amplitude of mIPSC in tSCI group was 
significantly higher than the sham group (Sham: 13.3 ± 0.2 pA; tSCI: 14.0 ± 0.2 pA. p < 0.01), which became 
decreased in the tSCI + LED group (tSCI + LED: −13.1 ± 0.2 pA. p < 0.01 when the tSCI and tSCI + LED 
groups were compared). (D-E). There were no significant differences in cumulative distributions of mIPSC 
frequencies and amplitudes (p > 0.05, K-S test).
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reorganization is not contradictory with the homeostatic mechanism we propose here, because neuronal activ-
ity and plasticity intricately connect to each other and changes in activity often trigger cortical reorganization. 
For example, visual deprivation causes changes not only in neuronal activity, but also in dendrites and spines10. 
Cortical deafferentation causes synchronized slow wave activity, which promotes axon sprouting47.
Direct electrical stimulation of the S1 has been shown to cause pain sensation in human subjects during sur-
gery48, which is apparently contradictory to our results that optogenetic stimulation of the S1 reduced pain-like 
behavior. However, there are several major differences between optogenetic stimulation and the effect of S1 elec-
trical stimulation. First, the neuronal populations being activated are different. Optogenetic stimulation in our 
experiment activated only cortical excitatory neurons, with the majority of these being layer V pyramidal neu-
rons, which is in contrast to activation of both pyramidal and interneurons by intracortical electrical stimula-
tion. Second, the number of neurons being activated by the optogenetic stimulation is probably larger and more 
diffusely distributed than that evoked by electrode stimulation. Third, more importantly, the chronic effect of S1 
optogenetic stimulation occurred after hours of cortical stimulation, and the effect peaked in 3–5 days, which is 
in contrast with intraoperative acute S1 stimulation that exacerbated pain in human patients. Furthermore, our 
electrophysiological data showed that chronic optogenetic stimulation of the S1 actually reduced S1 excitability 
through decreasing spontaneous AP firing, increasing AP threshold, and greatly reducing excitatory synaptic 
input (Figs 5–6). The effect of corpus callosotomy on eliminating optogenetically induced analgesia (Fig. 6) fur-
ther supports a role of activity enhancement on relieving pain. Interestingly, a recent study showed that optoge-
netic stimulation of S1 activity using beta and gamma frequencies acutely block pain transmission49. While motor 
cortical stimulation is a common treatment for refractory chronic pain including neuropathic pain and phantom 
pain, S1 stimulation is also shown to be effective in relieving pain in human and animal studies50,51.
Our findings suggest that chronic optogenetic stimulation normalizes electrophysiological alterations that 
underlie cortical hyperexcitability in the tSCI model. Because the layer V pyramidal neurons have a dominant 
effect in determining activity level of cortical columns and our optogenetic stimulation on the ChR2 transgenic 
Figure 10. Pharmacological enhancement of cortical excitatory activity also reduces mechanical 
hypersensitivity. (A). In vivo two photon images from a GCaMP6 tSCI mouse show low spontaneous activity at 
baseline (left) and dramatically enhanced activity after applying 20 mM bicuculline solution on the S1 cortical 
surface. The bicuculline application induced highly synchronized rhythmic epileptiform activities of the 
cortex, suggesting that GABAA receptor activation is inhibitory (n = 2 mice). Scale bar: 20 µm. (B). Implanting 
bicuculline-Elvax (200 µm thick) on the pial surface of the S1 at day 1 and day 21 post-tSCI (black arrows) 
significantly increased the withdrawal threshold of bilateral paws (n = 4 in blank-Elvax and n = 6 in bicuculline-
Elvax group). **p < 0.01; ***p < 0.001.
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mice mainly activates these neurons, our patch clamp recordings were made from these neurons. Although layer 
V pyramidal neurons and layer II/III neurons (which we imaged) have different layer-specific functions in neural 
coding, they are interconnected to function as cortical columns and their activity is often synchronized with 
similar firing frequency52,53. Therefore, changes in activity and excitability detected in layer II/III and layer V 
are likely consistent. The reduced spontaneous firing could be attributed to increased AP threshold, decreased 
input resistance, and reduced mEPSC frequency. Although the optogenetic stimulation also increased the ampli-
tude of mEPSC, such increase was small in contrast to the great decrease in mEPSC frequency (Fig. 6B,C). 
Similarly, the decrease in the amplitude of mIPSCs after optogenetic stimulation was also small and the fre-
quency was unchanged (Fig. 7B,C). Thus, the net effect of optogenetic stimulation on pyramidal neurons is a 
significant reduction in excitatory synaptic drive, which would decrease network excitability and cortical activity. 
Consistently, electrical stimulation or bicuculline treatment of cortical neurons also decreases spontaneous and 
burst spike activity and reduces evoked EPSP strength54,55. Therefore, enhancing cortical activity is correlated with 
homeostatic reduction of spontaneous firing and neuronal excitability.
The effectiveness of chronic cortical release of bicuculline in relieving neuropathic pain (Fig. 8) is in contrast 
to a generally accepted concept that inhibiting cortical excitation relieves neuropathic pain. For example, cortical 
infusion of GABAA receptor agonists (e.g. muscimol or GABA) relieves pain, while acute cortical injection of 
GABAA receptor antagonists induces burst spiking and pain35,56,57. These apparently conflicting findings suggests 
that two opposite strategies may be used for controlling neuropathic pain. One strategy is to directly suppress 
cortical hyperexcitability in neuropathic pain by directly suppressing network excitatory activity or enhancing 
inhibition, such as the analgesic effect of locally applied muscimol or the use of specific antiepileptic drugs for 
pain treatment4,58. The other strategy we propose here is to enhance cortical excitatory activity so that the home-
ostatic mechanism takes effect and intrinsically reduces neuronal hyperexcitability. The effectiveness of cortical 
stimulations on neuropathic pain may be explained by this mechanism17. Similarly, a recent study showed that 
pharmacologically or optogenetically stimulating dopamine neurons of the ventral tegmentum can homeostati-
cally reduce neuronal hyperactivity and reverse depression related behavior59.
Although we show that enhancing cortical activity is sufficient to reduce network hyperexcitability and con-
trol neuropathic pain, involvements of other mechanisms such as activations of brain inhibitory pathways and 
descending projections cannot be ruled out16,60. Such changes may result from descending activation of subcorti-
cal nuclei and dorsal horn of the spinal cord and/or from reactions of pain pathways to reduced cortical excitabil-
ity following activity enhancement. Given the complexity and interconnectivity of the nociceptive system in the 
brain and spinal cord, dissecting out these potential pathways is beyond the scope of this study.
Controlling nociceptive hyperexcitability is a major strategy for controlling neuropathic pain. However, 
directly suppressing such hyperexcitability has unsatisfactory efficacy57. By demonstrating a role of homeostatic 
plasticity in neuropathic pain, we provide the first evidence that enhancing cortical excitatory activity per se is 
sufficient to reduce network hyperexcitability and relieve neuropathic pain, which may not only provide a mecha-
nistic explanation for the effectiveness of cortical stimulation in controlling refractory neuropathic pain, but also 
reveal a novel strategy for developing pharmacological treatment for neuropathic pain. Furthermore, enhancing 
cortical activity may be beneficial in controlling other neurological disorders featuring deafferentation-initiated 
cortical hyperexcitability, such as phantom limb pain, tinnitus, and acquired epilepsy9,27. Indeed, repetitive 
transcranial magnetic stimulation and electrical cortical stimulation are found promising for controlling these 
conditions51,61,62.
Materials and Methods
Animal models of neuropathic pain and Von Frey test. All experimental procedures were approved 
by the Animal Care and Use Committee of the Institutional Guide for the Care and Use of Laboratory Animals at 
Indiana University School of Medicine. Animal procedures adhered to guidelines outlined within the Guide for 
and Care and Use of Laboratory Animals of the National Institutes of Health, with ethical guidelines outlined by 
the International Association for the Study of Pain. All behavioral data collection and analysis was performed by 
blinded individuals. Tibial nerve injury (TNI) and tSCI models were performed on adult (6–8 weeks old) male 
Thy1-Channelrhdopsin 2 (ChR2) transgenic mice.
The mice were anesthetized with ketamine/xylazine (87.7/12.3 mg/kg, i.p.). For TNI, after a small incision was 
made on the left leg to expose the tibial nerve, a silk thread was used to make three consecutive loose ligations 
around it and the nerve was transected distal to the ligation. For tSCI, the abdominal cavity of the mice was 
opened and the abdominal aortic artery was exposed at the level of the left renal artery. The aortic artery was then 
isolated and blocked with a metal clip (vascular micro bulldog) for 60 minutes. Mice in the sham groups received 
similar surgical procedures without actual nerve ligation (in TNI) or aortic occlusion (in tSCI).
Mechanical hypersensitivity was measured using a mechanical Von Frey anesthesiometer. Calibrated Von 
Frey filaments measuring 100 μm in diameter capable of exerting bending forces of 5, 10, 20, 40, 60, 80, and 120 
mN were applied to the plantar surface of the animal hindpaw63. Each stimulus lasted approximately 1 second and 
had a 10–15 second intermission between applications. Increasing Von Frey filaments were applied until a paw 
withdrawal was observed and the corresponding stimulation intensity was recorded. The test was conducted by a 
research analyst blinded to treatments and group assignment.
In vivo two-photon imaging for evaluating neuronal activity, effects of bicuculline, and opto-
genetic stimulation on cerebral circulation. Under ketamine/xylazine (87.7/12.3 mg/kg, i.p.) anes-
thetization, cranial windows were prepared in adult GCaMP6s transgenic mice and were centered at −2.5 mm 
bregma and 2.5 mm lateral, using a previously described technique64. For imaging, the mice were sedated with 
chlorprothixene35, and calcium transients of cortical layer II/III neurons were imaged at 4-5 frames per second for 
3 minutes using a two-photon microscope (Prairie Technologies)10. Excitation was provided by a tunable Maitai 
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Ti:sapphire laser (Newport, Mountain View, CA) tuned to 900 nm. Band-pass filtered fluorescence (560–660 nm) 
was collected by photomultiplier tubes of the system. The same fields were identified and imaged at all different 
time points.
For data analysis, neurons were manually selected based on average projections of image stacks combined with 
looking through the whole image stacks. Raw fluorescence (F) was measured as average fluorescence of pixels lying 
within a cell in each frame and background fluorescence (Fo) was measured as mean of 2 sites that were just around 
the cell and contained no neuronal structures. ΔF/F signals were calculated as (F- Fo)/Fo. Cell activity was measured by 
both mean integrated fluorescence and ratio of active neurons10. Integrated fluorescence was calculated by integrating 
all fluorescence above a threshold of 20% ΔF/F. The threshold was used to eliminate possible influence of noise. Active 
neurons were defined as cells that had fluorescence intensity above threshold level at least once. The ratio of active 
neurons at a given time period was calculated by dividing the number of active cells by the total number of cells in that 
particular imaging field10. Both values of each mouse at different time points were normalized to the baseline levels.
To determine whether bicuculline had an excitatory or inhibitory effect on cortical pyramidal neurons of neu-
ropathic pain model, we prepared tSCI in three GCaMP6 mice as described above. On day 3 after the surgery, the 
mice were anesthetized with ketamine/Xylyzine and acute cranial windows were made over the S1 area. Following 
baseline imaging of activity of layer II/III GCaMP neurons, 20 mM bicuculline was applied onto the pial surface, 
and the same imaging fields were repeatedly imaged every 15–30 minutes for up to 5 hours.
To evaluate the effect of light stimulation with blue LED on cerebral blood circulation, four C57BL mice were 
used for in vivo two-photon imaging. Cranial windows were prepared using the same technique as described 
above. Two weeks later, the mice were sedated by an intraperitoneal injection of chlorprothixene, and followed 
by an intraperitoneal injection of 200 µL 0.4 mg/mL Sulforhodomine 101 at 15 minutes before imaging to label 
the blood plasma. Arterioles and venules (20–30 µm diameters) were identified based on vessel shape, direction 
of blood flow relative to branching pattern, and flow velocity. For each mouse, two arterioles and two venules 
on the S1 were imaged in both frame (512 × 512 pixels) and line scan (1 millisecond [ms] per line) modes using 
PrairieView software of the two-photon system. Following a baseline imaging, the same light pulses used for 
optogenetic stimulation were applied to the cranial window for 15 minutes. Then the same blood vessels were 
imaged again to compare potential changes in vessel diameter and red blood cell (RBC) velocity after light stim-
ulation. Imaging analyses were made with Metlab and NIH ImageJ software. Vessel diameters were manually 
measured from the maximum distance of longitudinal sections of the vessels. RBC velocity was determined from 
line-scan images using a Metlab script based on a technique described by Drew et.al.65.
Cortical optogenetic stimulation, virus injection, and corpus callosotomy. For optogenetic stimu-
lation, the skull above the S1 was exposed and the periosteum was cleaned. After a layer of cyanoacrylate glue was 
applied, a circular area of the skull on top of the S1 region (~3 mm diameter) was removed and a circular cover 
glass was sealed onto the edge of the skull to make a cranial window. A high-intensity blue LED was then glued 
on top of the cover glass, with a circular area of ~2.5 mm diameter being exposed to the light and the outer region 
being blocked with a piece of opaque tape. The LED was controlled by a miniature circuit that generated a burst of 
3 pulses at 33 Hz once every 3 seconds. Two sessions of 3-hour stimulation with a 2-hour break in between were 
applied daily to the contralateral S1 on the second day following TNI or tSCI for 1–3 weeks.
For focal infection of ChR2 virus, 1 µL of an AAV1.CaMKIIa.hChR2(H134R)-mCherry.WPRE.hGH 
(Addgene26975, purchased from the Penn Vector Core of the University of Pennsylvania School of Medicine) was 
injected into the center of HL-S1 area using a glass pipette. After the pipette was inserted to about 650 µm below 
the pial, injection was made with a microinjection system in 10 minutes. The pipette was then kept in position 
for another 10–15 minutes. Optogenetic stimulation was applied in 2 weeks after viral injection, using the same 
protocol with two sessions of 3 hours for 7 days.
Corpus callosotomy was made by modifying a previously described technique66. After anesthetization, a 4 mm 
long slit was drilled in the skull, at 0.5 mm lateral to the midline and parallel to the S1. An “L”-shaped bent 
34-gauge needle was inserted into the midline between two cortical hemispheres and lowered vertically 1.5 mm 
into cortical tissue to cut the corpus callosum, then lifted to underneath the pia and withdrawn. To visualize 
the cutting path and transected axons from callosotomy, a needle that was coated with a thin layer of lipophilic 
fluorescent dye DiI was used to make the callosotomy in 3 mice. The mice were sacrificed, perfused, and fixed in 
48 hours after the surgery. Coronal cortical slices (50 µm) were cut and imaged under a fluorescence microscope.
C-fos staining. Four mice were assigned to each of the naïve, naïve + LED, and tSCI + LED groups. For the LED 
groups, the mice received 1.5 hours of optogenetic stimulation using the protocol described above. Then, the mice were 
immediately anesthetized with sodium pentobarbital (150 mg/mL) and transcardially perfused with 50 mL of 0.9% 
saline, followed by 50 mL of 4% paraformaldehyde. After the brains were removed and fixed overnight at 4 °C, they 
were transferred to a 30% sucrose solution and stored at 4 °C until isotonic with the solution. A freezing microtome 
(Leica Biosystems, IL) was used to cut coronal sections of the S1 to 30 μm thickness. The sections were placed in cryo-
protectant (30% glycerol and 30% ethylene glycol of 0.1 M phosphate buffer). After the sections were washed 3 times in 
0.1 M phosphate buffer solution (PBS), they were incubated overnight at room temperature in 1:700 rabbit polyclonal 
anti-c-fos antibody (Catalog No. ABE457, Millipore, MA), followed by incubation for 2 hours at room temperature in 
1:200 donkey anti-rabbit antibody. The sections were imaged under a florescence microscope.
Preparation and implantation of drug-containing Elvax. Elvax implants were prepared as described 
previously67–69. Briefly, ethylene vinyl acetate copolymer (EVA) (40% vinyl acetate by weight, DuPont, St. Louis, 
USA) was washed in 100% ethanol several times and dissolved in dichloromethane to give a 10% solution (w/v). 
A 100 µL sample of double-distilled water (for blank implants) or an aqueous solution of bicuculline methiodide 
www.nature.com/scientificreports/
1 5SCieNTifiC REPORts | 7: 12743  | DOI:10.1038/s41598-017-12972-6
was added to the Elvax/dichloromethane solution. The final concentration of bicuculline was 10 mM. The suspen-
sion was vortexed for 30 minutes and poured into a glass tube and placed on dry ice for 30 minutes. After storage 
at −20 °C for 7 days, the Elvax was cut into 200 µm slices using a vibratome and stored at −20 °C until use.
For implantation, mice were anesthetized with ketamine/xylazine (87.7/12.3 mg/kg, i.p.). After a craniotomy was 
made over the left S1 region, a slice of Elvax (2 × 2 mm) containing vehicle or drug was placed on the cortical surface 
to cover the S1 area. The craniotomy was covered with a piece of sterile plastic wrap, and the skin was sutured.
Recording cortical sensory evoked potentials in vivo and patch clamp recording in vitro. 
Cortical sensory-evoked potentials were recorded from the HL-S1 in vivo. In anesthetized C57BL mice, small 
holes (~0.5 mm) were drilled on the skull above HL-S1 (1 mm posterior to bregma and 1.8–2 mm lateral to the 
midline) and above the cerebellum. Stainless steel screws were implanted into these holes as recording and refer-
ence electrodes respectively. Baseline responses were recorded at 7–10 days after screw installation in awake ani-
mals. To induce sensory-evoked potentials, an acupuncture needle was inserted into the paw of the contralateral 
hindlimb. Electric stimulus (0.2 ms square pulses at 0.5 mA, once every 20 seconds) was applied and gradually 
increased until a response was induced. Twice the level of this threshold current was used for inducing cortical 
evoked potentials. The responses were measured from an average of 20 traces. Following the baseline recordings, 
the mice received tSCI surgery, followed by optogenetic stimulation on the second day after the surgery for 5 days.
For in vitro patch clamp recording, brain slices (350 µm thick) containing HL-S1 were cut and maintained 
using previously described procedures70. Patch clamp recordings were made at room temperature (22-23 °C) from 
layer V pyramidal neurons. Glass patch electrodes had an impedance of 3–5 MΩ when filled with intracellular 
solution containing (in mM): 20 KCl, 100 cesium gluconate, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, 10 sodium phos-
phocreatine and 3 QX-314. For current clamp recordings, K-gluconate based solution was used, which contained 
(in mM): 100 K-gluconate, 20 KCl, 10 HEPES, 4 Mg-ATP, 0.3 NaGTP and 10 sodium phosphocreatine. To meas-
ure spontaneous action potential (AP) firing rate, current clamp recordings were made by adjusting the mem-
brane potentials to −60 mV or −65 mV and in a modified artificial cerebrospinal fluid (ACSF) that contained 
(in mM): 124 NaCl, 3.5 KCl, 0.5 MgCl2, l.25 NaH2PO4, 26 NaHCO3, 1 CaCl2, and 25 Dextrose23. For measuring 
miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs), 1 µM tetrodotoxin (TTX) was 
added into the ACSF. The reversal potentials were determined by voltage clamping the postsynaptic neurons to 
different potentials (in 5 mV increments) between −55 and −30 mV for mIPSCs and between −5 and +15 mV 
for EPSCs. With the above internal solutions and modified ACSF, the measured average reversal potentials were 
11.3 ± 1.2 mV for mEPSCs and −40.5 ± 1.8 mV for mIPSCs respectively.
Intrinsic properties and AP firings were determined from neuronal responses to a series of 500 ms hyperpolar-
izing and depolarizing currents pulses (25–50 pA steps) under current clamp mode. Analysis of intrinsic properties 
was done using Clampfit 9.0 software. Resting membrane potential was measured as the membrane voltage after 
break-in and no current was injected. Liquid junction potential was not adjusted. Input resistance was determined 
from the slope of a best-fit-line through the linear segment of a voltage-current relationship. The first AP elicited by 
the lowest current injection was used for measuring AP properties. AP threshold was determined at the voltage level 
when voltage deflection exceeded 10 mV/ms. Spontaneous AP spikes, mEPSCs, and mIPSPs were detected using 
event detecting software based on the rise time, event width, minimal amplitude, and event duration71. The detector 
parameters were manually adjusted and tested to ensure a >95% detection of all events. Cumulative probability 
distributions were plotted by randomly selecting 100 events from each neuron in each group.
Statistics. Data are presented as mean±SEM. Statistical significances were determined using nonparametric 
Mann-Whitney test for spike rate, two-way repeated measure analysis of variance (ANOVA) for in vivo calcium 
imaging data and pain threshold, and one-way ANOVA for mean amplitude and frequency of mEPSCs and mIP-
SCs, followed by appropriate post hoc tests. Statistical significance was set as p < 0.05. Comparisons of cumulative 
distributions of synaptic events were made with Kolmogorov-Smirnov test (K-S test).
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